Essentials Masterclass: Migraine Cocktail

Acute headache treatment in the ED starts with ruling out dangerous secondary causes while relieving symptoms aggressively. Migraine cocktails work best when anti-dopaminergic agents lead, opioids stay off the table, and symptom response never substitutes for the diagnostic workup.

ED Migraine Cocktail Strategy

• Dangerous headache differential: Subarachnoid hemorrhage, CNS infection, cervical artery dissection, and cerebral venous sinus thrombosis stay on the board even when the exam is reassuring, a diagnostic mindset we sharpen in the episode.
• Treatment response trap: Headache resolution does not rule out a dangerous cause, so the diagnostic workup should run independently of symptom control rather than being guided by whether the cocktail works.
• First-line antidopaminergic therapy: IV anti-dopaminergic agents are the preferred first move for acute migraine, with metoclopramide, prochlorperazine, droperidol, and haloperidol forming the core options.
• Why not opioids: Opioids are not recommended for ED headache management, including a Level 1 ACEP recommendation against them because they worsen variability in care without addressing migraine biology.
• Second-line ketorolac ceiling: When the first dose is incomplete, another anti-dopaminergic plus IV ketorolac is a strong next step, and ketorolac has an analgesic ceiling at 15 mg rather than higher doses.
• Refractory rescue options: By the third and fourth line, ergot alkaloids, peripheral nerve blocks, and selected emerging therapies enter the picture, with practical sequencing nuances we get into in the chapter.

Adjuncts and Emerging Therapies

• Fluids and diphenhydramine limits: IV fluids are not first-line unless dehydration is present, and diphenhydramine offers only modest headache benefit while reliably adding grogginess.
• Ergot contraindication check: Ergot alkaloids can help refractory migraine but are contraindicated in cardiovascular disease and after recent triptan use, a safety pause worth making before escalation.
• Peripheral nerve block role: Peripheral nerve blocks are relatively easy bedside interventions for refractory primary headache, typically using lidocaine or bupivacaine when repeated medications are failing.
• Propofol as emerging option: Propofol is among the best-studied emerging rescue therapies for refractory migraine, used in subanesthetic dosing rather than procedural-sedation style administration.
• Ketamine mixed evidence: Ketamine has a more inconsistent track record than propofol in acute migraine, so it is not a first-line agent despite growing familiarity with subdissociative dosing.
• Other nonopioid alternatives: Magnesium, valproic acid, and octreotide round out the nonopioid rescue list for selected refractory headaches. We cover where these fit on the show.

References

1. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Acute Headache:, Godwin SA, Cherkas DS, et al. Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Headache. Ann Emerg Med. 2019;74(4):e41-e74. PMID: 31543134 
2. Soleimanpour H, et al. Improvement of refractory migraine headache by propofol: case series. Int J Emerg Med. 2012;5(1):19. Published 2012 May 15. PMID: 22587626. 
3. Chah N, et al. Efficacy of ketamine in the treatment of migraines and other unspecified primary headache disorders compared to placebo and other interventions: a systematic review. J Dent Anesth Pain Med. 2021;21(5):413-429. PMID: 34703891.
4. Edlow JA, et al; American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute headache. Ann Emerg Med. 2008;52(4):407-436. PMID: 18809105.
5. Nicolodi M, Sicuteri F. Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. Int J Clin Pharmacol Res. 1995;15(5-6):181-189.PMID: 8835616.
6. Bigal ME, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002;22(5):345-353.  PMID: 12110110
7. Kapicioğlu S, et al. Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide, SMS 201-995). Cephalalgia. 1997;17(1):27-30. PMID: 9051332.
8. Friedman BW, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014;82(11):976-983. PMID: 24523483.
9. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36(7):995-997. PMID: 3520384.
10. Patel D, et al. Effectiveness of Peripheral Nerve Blocks for the Treatment of Primary Headache Disorders: A Systematic Review and Meta-Analysis. Ann Emerg Med. 2022;79(3):251-261. PMID: 34756448.